De novo severe pemphigus vulgaris following SARS-CoV-2 vaccination with BBIBP-CorV.
作者信息
Saffarian Zahra, Samii Rana, Ghanadan Alireza, Vahidnezhad Hassan
机构信息
Imam Khomeini Hospital, Tehran University of Medical Science, Tehran, Iran.
Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
出版信息
Dermatol Ther. 2022 Jun;35(6):e15448. doi: 10.1111/dth.15448. Epub 2022 Mar 20.
Abstract
摘要
相似文献
1
De novo severe pemphigus vulgaris following SARS-CoV-2 vaccination with BBIBP-CorV.
Dermatol Ther. 2022 Jun;35(6):e15448. doi: 10.1111/dth.15448. Epub 2022 Mar 20.
2
Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation.
Dermatol Ther. 2022 May;35(5):e15396. doi: 10.1111/dth.15396. Epub 2022 Mar 15.
3
Pemphigus vulgaris with advanced hypopharyngeal and gastric cancer following SARS-CoV-2 vaccination.
J Dermatol. 2023 Feb;50(2):e74-e75. doi: 10.1111/1346-8138.16539. Epub 2022 Jul 29.
4
Reply to 'development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2' by Solimani F et al.
J Eur Acad Dermatol Venereol. 2022 Dec;36(12):e976-e978. doi: 10.1111/jdv.18398. Epub 2022 Jul 12.
5
Two cases with new onset of pemphigus foliaceus after SARS-CoV-2 vaccination.
Dermatol Ther. 2022 Nov;35(11):e15827. doi: 10.1111/dth.15827. Epub 2022 Sep 30.
6
De novo pemphigus vulgaris and pemphigus foliaceus development following COVID-19 infection and vaccination: Matched case-control study.
J Eur Acad Dermatol Venereol. 2024 May;38(5):e374-e376. doi: 10.1111/jdv.19783. Epub 2024 Jan 12.
7
Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco.
BMC Public Health. 2022 Aug 20;22(1):1584. doi: 10.1186/s12889-022-14016-9.
8
Pemphigus foliaceus triggered after inactivated SARS-CoV-2 vaccine: Coincidence or causal link?
Dermatol Ther. 2022 Oct;35(10):e15775. doi: 10.1111/dth.15775. Epub 2022 Aug 28.
9
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans.
Geroscience. 2021 Oct;43(5):2321-2331. doi: 10.1007/s11357-021-00471-6. Epub 2021 Oct 11.
10
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
Nat Commun. 2022 Jun 27;13(1):3654. doi: 10.1038/s41467-022-31379-0.
引用本文的文献
1
Pemphigus and Bullous Pemphigoid Following COVID-19 Vaccination: A Systematic Review.
Viruses. 2024 Dec 9;16(12):1896. doi: 10.3390/v16121896.
2
Severe aggravation and possible triggering of pemphigus vulgaris following COVID-19 vaccination: report of two cases.
An Bras Dermatol. 2024 Sep-Oct;99(5):758-762. doi: 10.1016/j.abd.2023.04.012. Epub 2024 Jun 3.
3
New Onset and Exacerbation of Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Systematic Review.
Vaccines (Basel). 2024 Apr 26;12(5):465. doi: 10.3390/vaccines12050465.
4
A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports.
Eur J Med Res. 2023 Nov 26;28(1):542. doi: 10.1186/s40001-023-01531-7.
5
Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine.
Front Med (Lausanne). 2023 Jan 19;10:1112823. doi: 10.3389/fmed.2023.1112823. eCollection 2023.
6
Purpuric dermatosis and lymphocytic vasculopathy following SARS-CoV-2 vaccination: Report of two patients.
Dermatol Ther. 2022 Nov;35(11):e15898. doi: 10.1111/dth.15898. Epub 2022 Oct 10.
7
Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review.
J Autoimmun. 2022 Oct;132:102898. doi: 10.1016/j.jaut.2022.102898. Epub 2022 Aug 24.
8
Exacerbation of Autoimmune Bullous Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Is There Any Association?
Front Med (Lausanne). 2022 Jul 19;9:957169. doi: 10.3389/fmed.2022.957169. eCollection 2022.
本文引用的文献
1
Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine.
Oral Dis. 2022 Nov;28 Suppl 2:2612-2613. doi: 10.1111/odi.14089. Epub 2021 Dec 5.
2
Cutaneous findings following COVID-19 vaccination: review of world literature and own experience.
J Eur Acad Dermatol Venereol. 2022 Feb;36(2):172-180. doi: 10.1111/jdv.17744. Epub 2021 Nov 2.
3
Oral pemphigus after COVID-19 vaccination.
Oral Dis. 2022 Nov;28 Suppl 2:2597-2598. doi: 10.1111/odi.14034. Epub 2021 Oct 7.
4
COVID-19 Vaccines and the Skin: The Landscape of Cutaneous Vaccine Reactions Worldwide.
Dermatol Clin. 2021 Oct;39(4):653-673. doi: 10.1016/j.det.2021.05.016. Epub 2021 May 31.
5
Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2.
J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e649-e651. doi: 10.1111/jdv.17480. Epub 2021 Jul 12.
6
Skin Manifestations in COVID-19 Patients: Are They Indicators for Disease Severity? A Systematic Review.
Front Med (Lausanne). 2021 Feb 16;8:634208. doi: 10.3389/fmed.2021.634208. eCollection 2021.
7
Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.
Clin Immunol. 2020 Aug;217:108480. doi: 10.1016/j.clim.2020.108480. Epub 2020 May 24.
8
The Genetics of Pemphigus Vulgaris.
Front Med (Lausanne). 2018 Aug 14;5:226. doi: 10.3389/fmed.2018.00226. eCollection 2018.
9
Pemphigus trigger factors: special focus on pemphigus vulgaris and pemphigus foliaceus.
Arch Dermatol Res. 2018 Mar;310(2):95-106. doi: 10.1007/s00403-017-1790-8. Epub 2017 Nov 6.
10
Pemphigus.
Nat Rev Dis Primers. 2017 May 11;3:17026. doi: 10.1038/nrdp.2017.26.
Zotero 插件